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Abstract 28 
Objective: Research into cardiovascular disease (CV) prevention has demonstrated a variety of ultrasound 29 
(US) markers predicting risk in the general population, but which have been scarcely used for polycystic ovary 30 
syndrome (PCOS). Obesity is a major factor contributing to CV disease in the general population, and it is 31 
highly prevalent in PCOS. However, it is still unclear how much risk is attributable to hyperandrogenism. This 32 
study evaluates the most promising US CV risk markers in PCOS and compares them between different PCOS 33 
phenotypes and BMI values. 34 
Design: Women fulfilling the Rotterdam criteria for PCOS were recruited from our outpatient clinic for this 35 
cross-sectional study. 36 
Methods: Participants (n = 102) aged 38.9±7.4 years were stratified into the four PCOS phenotypes and the 37 
three BMI classes (normal-weight, overweight, obese). They were assessed for clinical and biochemical 38 
parameters together with the following US markers: coronary intima-media thickness (cIMT), flow-mediated 39 
vascular dilation (FMD), nitroglycerine-induced dilation (NTG), and epicardial fat thickness (EFT). 40 
Results: There was no statistical difference among the four phenotypes in terms of cIMT, FMD, NTG or EFT, 41 
however all the US parameters except NTG showed significant differences among the three BMI classes. 42 
Adjusting for confounding factors in multiple regression analyses, EFT retained the greatest direct correlation 43 
with BMI, and cIMT remained directly correlated but to a lesser degree. 44 
Conclusions: This study showed that obesity rather than the hyperandrogenic phenotype negatively impacts 45 
precocious US CV risk markers in PCOS. In addition, EFT showed the strongest association with BMI, 46 
highlighting its potential for estimating CV risk in PCOS. 47 
  48 
1. Introduction 49 
Polycystic ovary syndrome (PCOS) is a multifactorial condition with a complex pathogenesis and a very 50 
polymorphic phenotype (1). In reproductive-age women, prevalences of between 6% and 20% have been 51 
estimated (2). There appears to be a higher prevalence of obesity, particularly the abdominal phenotype, 52 
insulin resistance, overt diabetes mellitus (DM), dyslipidaemias and primary arterial hypertension (HTA) in 53 
PCOS, compared to the general population (3–5). Following these findings, further studies on the long-term 54 
cardiovascular (CV) morbidity in PCOS have been performed. However conflicting data have emerged from 55 
these studies regarding the incidence of CV events in what was perceived as a high-risk population (6–9).  56 
Pathophysiologically, vascular failure is preceded by atherosclerosis, which starts decades before the 57 
occurrence of the first obstructions of clinical relevance (10). The search for a cost-effective, reliable and non-58 
invasive indicator of this precocious process of vascular damage has spawned multiple ultrasound (US) CV 59 
risk markers, of which arguably the most promising are carotid intima media thickness (cIMT), flow-mediated 60 
vessel dilation (FMD), and epicardial fat thickness (EFT).  61 
In the general population, cIMT has been shown to be a better predictor of CV events than the Framingham 62 
Risk Score. In fact, cIMT has a specifically higher precision in women, and it has also been shown to be 63 
significantly higher in PCOS compared to controls (11,12). FMD has also been proven to be a good predictor 64 
of future CV events in the general population, and to be significantly impaired in PCOS patients (13,14). 65 
However, a lack of androgen profiling, a lack of comparisons between normal weight and overweight or obese 66 
PCOS patients, and disparate PCOS classifications in published studies preclude the association of these US 67 
markers with obesity, hyperandrogenism or different PCOS phenotypes in general, which may be the missing 68 
variables in estimating CV risk in PCOS.  69 
One study, conducted on menopausal women in the general population, demonstrated a positive correlation 70 
between cIMT and circulating androgens, specifically dehydroepiandrosterone sulphate (DHEAS) and 71 
androstenedione, thus suggesting a potential association between the hyperandrogenic phenotype and worse 72 
US CV risk markers also in PCOS (15). 73 
EFT has been relatively recently developed as an inexpensive, fast analogue for visceral fat measurement, as 74 
well as an extensively studied CV and metabolic risk factor, and it also correlates well with the current gold 75 
standard – abdominal MRI (16). EFT is an independent predictor of insulin resistance, adipocytokine levels 76 
and clinical coronary artery disease in the general population (17,18). In the PCOS population however, to 77 
date only six small-scale studies on EFT have been published , all on young subjects, with conflicting results 78 
on the value of EFT in PCOS compared to controls, and no consideration of PCOS phenotypes (19–24). 79 
Overall, existing studies on cIMT, FMD and EFT have either compared obese PCOS patients with obese 80 
controls, or PCOS and controls, without stratifying for BMI. Since obesity is one of the major factors contributing 81 
to CV morbidity, it merits consideration in PCOS when investigating CV risk markers. 82 
The aim of this cross-sectional study was to investigate the possible differences in the expression of precocious 83 
US CV risk markers among different PCOS phenotypes and BMI classes in reproductive age PCOS women. 84 
With this approach, we hoped to gain insights into the risk profile of PCOS patients for simpler screening and 85 
long-term follow-up. 86 
2. Materials and methods 87 
2.1. Participants 88 
This cross-sectional study originates from the analysis of data collected in 2009 in the context of a larger, 89 
ongoing longitudinal study aimed at estimating the prevalence and incidence of metabolic and CV diseases in 90 
a population of PCOS followed at the Endocrinology Unit of St. Orsola Hospital in Bologna, Italy. One hundred 91 
and two Caucasian PCOS women in reproductive age were included. The diagnosis of PCOS was made 92 
according to the Rotterdam criteria (25). Hyperandrogenism (HA) was defined as any of the following: presence 93 
of hirsutism, defined by the modified Ferriman-Gallwey score ≥8 (26), total testosterone above 0.7ng/mL, or 94 
free testosterone calculated by the Vermeulen formula higher than 9.52 pg/mL. Polycystic ovarian morphology 95 
(PCOM) was defined as presence of 12 or more follicles 2–9 mm in diameter, and/or increased ovarian volume 96 
>10 mL in at least one ovary, according to the 2004 ESHRE/ASRM recommendations (25). Oligo/anovulation 97 
was diagnosed with the occurrence of menstrual cycles lasting more than 35 days or less than 21 days, 98 
supported by the measurement of luteal phase progesterone being <2 ng/mL.  99 
Exclusion criteria were: hyperprolactinaemia, congenital adrenal hyperplasia, Cushing’s syndrome, androgen-100 
secreting tumours, thyroid disease, premature ovarian failure or other specific causes of amenorrhoea, DM, 101 
CV, renal or liver diseases. None of the subjects included in the study had taken estroprogestins, insulin 102 
sensitisers or other drugs that could interfere with steroid levels in the blood for at least three preceding months. 103 
The study was approved by the Ethics Committee of the Emilia Center Area of Emilia-Romagna Region (CE-104 
AVEC), and each woman gave informed consent. 105 
2.2. PCOS phenotyping 106 
Participants were grouped into four PCOS phenotypes based on the following criteria (27): 107 
 A: HA + oligo/anovulation + PCOM 108 
B: HA + oligo/anovulation 109 
C: HA + PCOM 110 
D: oligo/anovulation + PCOM 111 
In relation to BMI, these PCOS phenotypes were also subdivided into normal weight (18.5-24.9 kg/m2), 112 
overweight (25-29.9 kg/m2), and obese(≥30 kg/m2) classes, based on the WHO criteria for obesity (28).  113 
2.3. Protocol 114 
Participants underwent a complete medical examination, anthropometric measurements, blood sampling for 115 
metabolic parameters and hormones, and US study. For women with a regular menstrual period or mild 116 
oligomenorrhoea, blood samples were taken after an overnight fast in the first week following the start of 117 
spontaneous bleeding. Participants with moderate to severe oligo- and amenorrhoea were given oral 118 
medroxyprogesterone acetate to induce bleeding, after which the same protocol was followed. An oral glucose 119 
tolerance test (OGTT) with 75 g of glucose (Curvosio, Sclavo, Cinisello Balsamo, Italy) was performed to 120 
diagnose DM, based on glucose measurements at the start and at the 120 min mark of the test, according to 121 
American Diabetes Association criteria (29). US examination of cIMT, FMD, nitroglycerine test (NTG) and EFT 122 
were performed during the same examination by a single expert physician, who was blinded to the clinical data 123 
of the patients.  124 
2.4. Anthropometric and clinical measurements 125 
Participants had a physical examination which included body measurements (height, weight, waist 126 
circumference) and blood pressure. Height was measured without shoes and rounded to the nearest 0.5 cm; 127 
weight was measured in the morning, fasting, without clothes, upon emptying the bladder and bowels. BMI 128 
was calculated as weight (kg) divided by the square of height (m). Waist circumference was measured with 129 
the subjects standing, with a 1 cm wide measuring tape, according to WHO guidelines (28). Blood pressure 130 
was measured twice in the supine position, in the morning, after at least 3 min of rest before measurement, 131 
taking the average of two. In the case they differed >10mmHg, a third measurement was done, and the outlier 132 
rejected. Women were instructed not to drink coffee or water 3h before the examination. Patients were defined 133 
as having HTA if any of the following applied: use of antihypertensive medication; systolic arterial blood 134 
pressure ≥ 140 mmHg; diastolic pressure ≥ 90mmHg. Similarly, dyslipidaemia was defined as the presence of 135 
any of the following: use of hypolipidemic drugs; blood triglycerides ≥ 150 mg/dL; blood LDL ≥ 100 mg/dL. 136 
2.5. Biochemical assays  137 
Glucose, insulin, triglycerides, total and high-density lipoprotein (HDL) cholesterol, TSH, prolactin, LH, FSH, 138 
oestradiol and testosterone were measured by Modular Analytics E170 (Roche Diagnostics, Mannheim, 139 
Germany) and SHBG was measured by Immulite 2000 (Siemens Healthcare Diagnostics, Deerfield, Illinois), 140 
as reported elsewhere (30)  141 
LDL was calculated using the Friedewald formula (31). Insulin resistance was calculated using the homeostatic 142 
model assessment of insulin resistance (HOMA-IR) index (32). Free testosterone was calculated using the 143 
formula by Vermeulen (33).  144 
2.6. Ultrasound measurements 145 
2.6.1. cIMT 146 
To measure early atherosclerosis, we sonographically measured IMT of the common carotid artery wall (34). 147 
Measurement of cIMT was carried out using B-mode US image acquisition (Siemens 2004 US machine with 148 
the linear probe at 10 MHz) between 08:00h and 09:30h.  149 
Image acquisition included the evaluation of right and left common carotid arteries, 1 cm proximal to the carotid 150 
bulb. The left and right far walls of the carotid artery segments were visualised with standardized magnification 151 
(2 cm × 2 cm). The sonographer used different scanning angles to identify the maximum thickness of the IMT 152 
1 cm proximal to the carotid bulb to be measured. IMT was defined for the common carotid artery as the mean 153 
of the maximum wall thicknesses for the near and far walls on the right and left common carotid segments: 154 
(maximum left near wall + maximum left far wall + maximum right near wall + maximum right far wall) / 4. For 155 
each segment, IMT was defined as the average of three measurements. Intra-observer coefficient of variation 156 
was 4.5±1.9%. 157 
2.6.2. FMD 158 
The procedure was performed using the linear 10 MHz probe of a vascular US system (Siemens 2004 US 159 
machine). With the probe above the cubital fossa, a measurement of the average diameter of the brachial 160 
artery at rest was obtained. Then, 3-5 cm above the cubital fossa, the sphygmomanometer cuff was placed 161 
and inflated rapidly to above the systolic pressure (> 300 mmHg) and held for 5 minutes. The cuff was then 162 
rapidly deflated, with simultaneous repeated measurements of the arterial diameter taken every 20 seconds 163 
for 3 minutes. The FMD was calculated as the percentage difference between the maximal diameter after 164 
deflation of the cuff and the average diameter in basal conditions. After a 15-minute rest period following FMD, 165 
we repeated the measurements before and 3-4 minutes after administering 0.4 mg of sublingual nitroglycerine. 166 
Vascular reactivity (NTG) was calculated as the percentage difference between the maximal diameter post-167 
nitroglycerine and the average diameter at rest. Intra-observer coefficient of variation was 1.6±1.0% for NTG 168 
and 1.2±0.6% for FMD. 169 
2.6.3. EFT 170 
Measurements were taken using with the convex 3.5 MHz probe positioned between the 3rd and 4th intercostal 171 
space along the left parasternal line, with the patient lying in the left lateral decubitus position. Measurements 172 
were taken at the end-diastolic part of the cardiac cycle, following the peak of the QRS complex on ECG. 2D 173 
US was performed during normal respiration. Epicardial fat thickness was measured above the free part of the 174 
right ventricle, in the long and the short axis. Epicardial fat was identified as the anechogenic space inside the 175 
pericardial line; the thickness was measured perpendicular to the ventricle muscle wall in the end-diastole part 176 
of the cardiac cycle, as an average of three cycles. Measurements were standardised using the aortic annulus 177 
as the anatomic reference. 178 
2.7. Statistical analysis 179 
Continuous variables were summarized using mean ± standard deviation (SD) or median and interquartile 180 
range, as appropriate according to the distribution of the variable. Categorical variables were summarized 181 
using absolute and percentage frequencies.  182 
The anthropometric, biochemical, and CV US measurements were compared across the four PCOS 183 
phenotypes and the three BMI classes (normal weight, overweight, obese) using one-way analysis of variance 184 
(ANOVA) when the assumptions for this analysis were met. Otherwise, Welch’s test was used. Following a 185 
significant ANOVA F or Welch’s test, post-hoc pairwise tests were conducted using the Bonferroni or Games-186 
Howell test with a correction to the probability level for multiple comparisons. Free T was compared among 187 
the four PCOS phenotypes using the Kruskal-Wallis test. The relationship of CV US measures with BMI, used 188 
as a continuous variable, was investigated using Pearson’s correlation coefficient and multiple linear 189 
regression models, in order to adjust for potential confounders. These included age, waist circumference, type 190 
2 DM, smoking, HTA, fasting glucose, fasting insulin, free testosterone, HOMA2-IR, SHBG and FSH. A p value 191 
of <0.05 was considered statistically significant. All statistical analyses were carried out using IBM SPSS, 192 
version 25.0.  193 
3. Results 194 
The study sample was comprised of 102 PCOS women with a mean age of 38.9±7.4 years. A total of 29 195 
women (28.4%) were overweight and 38 (37.2%) were obese. A total of 26 patients (25.5%) were affected by 196 
HTA, 58 (56.9%) by dyslipidaemia, and 13 (12.7%) by type 2 DM. A total of 27 patients (26.5%) used metformin 197 
as an insulin-sensitizer and 78 (76.5%) had taken estroprogestins in the past. The four PCOS phenotypes 198 
produced subgroups of 38, 7, 46 and 11 women, phenotypes A to D respectively, who had a similar age, BMI 199 
and waist circumference, as well as a similar prevalence of smoking, HTA, dyslipidaemia, type 2 DM, and 200 
previous treatments with metformin or estroprogestins (Tables 1 and 2).  201 
No significant difference was found when biochemical parameters were compared among phenotypes (Tables 202 
1 and 2), except for total and free testosterone, which were significantly higher in phenotypes A and C than in 203 
phenotype D (Table 2). The four PCOS phenotypes had similar values of cIMT, FMD, NTG, and EFT (Table 204 
3). 205 
Conversely, when the study sample was subdivided into the three BMI classes (normal weight n=35, 206 
overweight n=29, obese n=38) significant differences appeared in all the CV US measurements except for 207 
NTG which had a borderline significance (Table 4). In particular, cIMT was significantly higher in obese than 208 
overweight and normal weight participants; FMD was significantly lower in obese than in normal weight and 209 
overweight participants; and EFT showed a significant increasing gradient with increasing BMI class (Table 4). 210 
When the BMI was used as a continuous variable, it significantly, directly and strongly correlated with cIMT 211 
(Pearson’s r = 0.604, p < 0.001) and EFT (r = 0.695, p < 0.001), and inversely and more weakly with FMD (rho 212 
= -0.290, p = 0.004) and NGT (rho = -0.243, p = 0.02). 213 
All the other variables investigated except for age, LH, total testosterone, oestradiol, and prevalence of 214 
smoking and previous estroprogestin users differed among BMI classes (Tables 5 and 6). In particular, free 215 
testosterone was significantly higher and SHBG was significantly lower in obese and overweight than in normal 216 
weight participants; FSH was significantly higher in overweight than in normal weight participants; fasting 217 
glucose and the prevalence of type 2 DM and of dyslipidaemia were significantly higher in obese than in normal 218 
weight participants; and waist circumference, insulin, HOMA-IR and systolic blood pressure showed significant 219 
increases with increasing BMI classes (Tables 5 and 6). Moreover, diastolic blood pressure and prevalence of 220 
HTA were significantly higher in obese than in normal weight and overweight participants (Table 5). 221 
The relationships BMI-cIMT and BMI-EFT remained significant after adjusting for age, DM, smoking, HTA, 222 
SHBG, FSH and free testosterone by multiple regression analyses, whereas the relationships BMI-FMD and 223 
BMI-NTG were no longer significant (Supplemental Table). Significant correlation was found between BMI and 224 
all US CV markers using the parametric Pearson’s test; when adjusting for age, DM, smoking, HTA, SHBG, 225 
FSH and free testosterone in the multiple regression analysis, BMI-cIMT and BMI-EFT pairs remained 226 
significant (Supplemental Table). 227 
4. Discussion  228 
To the best of our knowledge, this is the largest cross-sectional study evaluating US CV risk parameters in 229 
PCOS across different PCOS phenotypes and different BMI classes. In addition, this is the first study to 230 
simultaneously measure the most promising precocious US CV risk markers in PCOS, that is: cIMT, FMD, 231 
EFT and NTG. Interestingly, we found no significant differences in these US measurements between the four 232 
PCOS phenotypes, however we found significant differences between the three BMI classes. In particular, 233 
cIMT and FMD showed a significant difference between obese and both overweight and normal weight 234 
patients, while EFT showed significant differences among the three classes of BMI. In addition, after adjusting 235 
for the effect of age, DM, smoking, hypertension and for levels of SHBG, FSH and of free testosterone, EFT 236 
showed the greatest direct correlation with BMI, cIMT remained directly correlated, though to a lesser degree, 237 
while FMD showed no relationship with BMI.  238 
The fact that there the values of cIMT, FMD, EFT and NTG were similar among the four PCOS phenotypes 239 
was unexpected because hyperandrogenism has been suggested to be a risk factor for CV events both in the 240 
general population and in PCOS (35,36), although some studies do not support this hypothesis (15,37,38). 241 
One plausible explanation for this result could be the relatively young age of our population, which consisted 242 
of women in reproductive age. With advancing age and prolonged exposure to hyperandrogenaemia, it is 243 
possible that these parameters could change in a significantly different way, depending on the phenotype. At 244 
the time of the study, however, only three of our patients had a cIMT value above 1mm, considered by many 245 
as the cut-off for clinical significance (39). There are no similarly agreed-upon reference ranges for FMD, EFT 246 
or NTG. 247 
Another unexpected finding was that our four PCOS phenotypes did not differ in terms of anthropometry or 248 
metabolic parameters, or in the prevalence of HTA, dyslipidaemia or type 2 DM. These results are apparently 249 
in contrast with some of the few studies that have compared the PCOS phenotypes for metabolic alterations 250 
and which investigated a comparably aged PCOS population (40,41). However, in these studies, the BMI 251 
differed significantly among the PCOS phenotypes, and when the comparison among phenotypes was 252 
adjusted for BMI (35) or body fat (34) the differences disappeared. 253 
Obesity is known to have an important role in the metabolic disturbances of PCOS (42,43), and our study 254 
confirms these findings. In fact, our obese PCOS subgroup had the highest prevalence of type 2 DM, 255 
dyslipidaemia, hypertension, as well as higher fasting insulin levels and HOMA-IR score than overweight and 256 
normal weight subgroups.  257 
In addition, our obese PCOS subgroup had higher free testosterone than the normal weight subgroup. Since 258 
total testosterone was comparable among BMI classes, the difference in free testosterone stems from a 259 
significantly lower SHBG in obese patients. Low SHBG is a recognised feature of PCOS (38), particularly in 260 
the presence of insulin resistance, which accompanies almost all obese PCOS women when measured by the 261 
euglycaemic-hyperinsulinemic clamp (44,45). It is also considered a risk factor for type 2 DM (46), as well as 262 
a predictor of the therapeutic response to metformin (47). Whether low SHBG is also a CV risk factor is 263 
unknown, but this important question is not answered in this study. 264 
However, our study does suggest that overweight, and especially obese PCOS subjects could be exposed to 265 
a higher risk of CV events later in life, because we found a quantifiable association between BMI and early 266 
cardiovascular alterations detected by US. 267 
When the BMI was used as a continuous variable, it significantly, directly and strongly correlated with cIMT 268 
and EFT, and inversely, albeit more weakly, with FMD and NTG. In addition, the relationship BMI-cIMT and 269 
BMI-EFT remained significant, after adjusting for the other clinical and biochemical variables that deteriorated 270 
with increasing body weight.  271 
This result supports the hypothesis that excess adipose tissue may directly contribute to early endothelial 272 
dysfunction, probably through the maintained production of adipocytokines and a chronic low-grade 273 
inflammation (41,42,48). Many studies have demonstrated that obesity in PCOS is almost always 274 
characterized by an abdominal phenotype (49). Accordingly, in the present study waist circumference, which 275 
is a known CV risk factor, was found to have a high collinearity with BMI in the multiple regression analysis, 276 
thus making it superfluous in this specific analysis. 277 
In conclusion, this study demonstrates that obesity, rather than the hyperandrogenic phenotype, negatively 278 
impacts precocious ultrasound CV risk markers in PCOS, thus suggesting that the main driver of CV events in 279 
PCOS could be the concomitant metabolic disorders, and primarily obesity. In addition, compared with other 280 
US markers, we found that EFT has the strongest adjusted association with BMI, highlighting its potential for 281 
estimating CV risk in PCOS.  282 
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